cefminox

Cefminox is a semisynthetic, second-generation cephamycin antibiotic with broad-spectrum bactericidal activity, particularly effective against Gram-negative and anaerobic bacteria. It is beta-lactamase-stable and acts by binding to and inactivating penicillin-binding proteins (PBPs) on the inner membrane of bacterial cell walls, thereby inhibiting the cross-linking of peptidoglycan chains essential for cell wall strength and rigidity. This leads to weakening of the bacterial cell wall and subsequent lysis. Cefminox is approved for use in Japan for various infections including respiratory tract infections (such as pneumonia, bronchitis), urinary tract infections (such as nephropyelitis, cystitis), intra-abdominal infections (such as cholecystitis, peritonitis), pelvic cavity infections (such as pelvic peritonitis), skin/soft tissue infections, septicemia, and is also used in surgical prophylaxis. It has demonstrated high safety in postmarketing surveillance studies[1][2][3][4][5][7]. Additionally, preclinical research suggests that cefminox may act as a dual agonist of prostacyclin receptor (IP) and peroxisome proliferator–activated receptor gamma (PPARγ), potentially inhibiting pulmonary artery smooth muscle cell proliferation via upregulation of PTEN expression and cAMP production; however, this mechanism has not been established clinically[8].

Brand names

Meicelin

Other names

cefminoxcefminoxumalteporina84305-41-9